Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAKHZYRO post-marketing long-term use survey in hereditary angioedema
jRCT2031220105Active, not recruiting
- Sponsor
- Takeda
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of lanadelumab in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoint: Number of participants who experienced at least one treatment-emergent adverse event. Started May 2022; status: active, not recruiting.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2031220105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220105.